Neuro-Oncology: Brain Metastases In Ovarian Cancer- A Comprehensive Review (P7.254)

Monday, April 21, 2014

Brain Metastases In Ovarian Cancer- A Comprehensive Review (P7.254)

Neurology recent issues

OBJECTIVE: To review the literature on brain metastasis (BM) from ovarian cancer, and assess the frequency, anatomical, clinical and paraclinical information and factors associated with prognosis.BACKGROUND: Ovarian cancer is a rare cause of brain metastasis. Progressive neurologic disability often results and the prognosis is generally poor. A comprehensive review on this subject has not been published previously.DESIGN/METHODS:This systematic literature search used the Pubmed and Yale library search engine and included all relevant articles in English literature. A total of 66 publications were found, 57 of which were used representing 591 patients with BM from ovarian cancer.RESULTS: The median age of the patients was 54.3 years (range 20-81). A majority of patients (57.3%) had multiple brain lesions. The location of the lesion was cerebellar( 30%), frontal (20%), parietal (18%) and occipital (11% ) . Extracranial metastasis was present in 49.8% of cases involving liver (20.7%), lung(20.4%), lymph nodes (12.6%), bones (6.6%) and pelvic organs (4.3%). The most common symptoms were weakness (16%), seizures (11%), altered mentality (11%) visual disturbances (9%) and dizziness (8%). The interval from diagnosis of breast cancer to BM ranged from 0-133 months (median 24 ) and median survival was 8.2 months. Treatment included local radiation, surgical resection, stereotactic radiosurgery and medical therapy. Factors that significantly increased the survival were younger age at the time of ovarian cancer diagnosis and at the time of brain metastasis diagnosis, higher KPS score and multimodality treatment for the brain metastases.CONCLUSIONS:Ovarian cancer is a rare cause of brain metastasis. Development of brain metastasis among older patients and lower KPS score correlate with less favorable prognosis. The more prolonged survival after using multimodality treatment for brain metastasis is important information that can potentially impact the management of such brain metastasis in future.Study Supported by: no support

Disclosure: Dr. Pakneshan has nothing to disclose. Dr. Safarpour has nothing to disclose. Dr. Tavassoli has nothing to disclose. Dr. Jabbari has received research support from Allergan Inc., Merz Pharma, and Ipsen.

Original Article: http://www.neurology.org/cgi/content/short/82/10_Supplement/P7.254?rss=1